完整议程全公开！《药海共潮 创新共舞——2024国际药物研发论坛》重磅来袭！

会议议程

出席大咖

LUO Minmin

Born Jiangxi Province, LUO Minmin is a neurobiologist and serves as the Director of the Chinese Institute for Brain Research, Beijing (CIBR) and a New Cornerstone Investigator. He graduated with a BS degree in psychology from Peking University in 1995 and then went to the United States for further studies; he obtained a Master's degree in Computer Science from the University of Pennsylvania in 1997 and a Ph.D. in Neuroscience from the same university in 2000. From 2000 to 2004, he conducted postdoctoral research at HHMI and the Department of Neurobiology at Duke University. After returning to China in 2004, he has long served as an Investigator at the National Institute of Biological Sciences, Beijing. In 2005, he was awarded funding from the National Natural Science Fund for Distinguished Young Scholars. In 2018, he took on the additional role of Director of CIBR.

Adil Mardinoglu Bio

Professor Adil Mardinoglu works as a Professor of Systems Biology at the Centre for Host-Microbiome Interactions at King’s College London, UK, and Science for Life Laboratory (SciLifeLab) at KTH-Royal Institute of Technology in Sweden. At the helm of a 30-strong research team, Professor Mardinoglu spearheads the development of novel treatment strategies for metabolic and neurodegenerative diseases, as well as certain cancers, blending multiomics, systems biology, AI and experimental biology with drug development.

A key contributor to the Swedish Human Protein Atlas program, Professor Mardinoglu has aided in the construction of a comprehensive human tissue, subcellular, and pathology atlas, and he has been instrumental in developing the cell atlas within the international Human Cell Atlas initiative. His scholarly output includes around more than 250 research and review articles published in journals such as Science, Nature, Nature Biotechnology, Cell Metabolism, Nature Metabolism, Nature Communications, PNAS, Cell Reports, Molecular Systems Biology, and EbioMedicine. Furthermore, as a co-founder of SZA Longevity, BASH Biotech, ScandiBio Therapeutics, ScandiEdge Therapeutics, and Trustlife Therapeutics, he has made substantial entrepreneurial contributions to the biotech sector.

Ke Shuai, Ph.D.

Full Professor with Tenure at the Institute of Modern Biology, Nanjing University

Overseas High-Level Talent of the National Innovation Long-Term Program

Professor Emeritus at the University of California, Los Angeles (UCLA)

Chief Scientist of Innovative Drug Investment at Tianhui Capital

Professor Shuai obtained his Ph.D. in 1990 from the Albert Einstein College of Medicine in the United States. He then began his postdoctoral research at Rockefeller University, working in the lab of Professor James E. Darnell, a world-renowned scientist and recipient of the U.S. Presidential Science Medal. In 1994, Professor Shuai joined the University of California, Los Angeles (UCLA), and in 2004, he became a full professor with tenure at UCLA. In July 2021, he resigned from his long-held tenured position at UCLA to join the Institute of Modern Biology at Nanjing University full-time.

Professor Shuai is one of the primary discoverers of the JAK-STAT signaling pathway. He was the first in the world to identify that an important protein in interferon signaling is a transcription factor with specific DNA recognition functions (Shuai et al., 1992, Science), which was later named as STAT (Signal Transducer and Activator of Transcription) (Shuai et al., 1993, Science), and the STAT/JAK signaling pathway (Shuai et al., 1993, Nature; Shuai et al., 1994, Cell). His laboratory was the first to discover and name the PIAS (Protein Inhibitor of Activated STAT) family of proteins (Chung et al., 1997, Science; Liu et al., 2007, Cell; Liu et al., 2010, Science), demonstrating that PIAS proteins are key regulators of STATs. These groundbreaking discoveries have provided new avenues for clinical treatment and drug development. Professor Shuai's research has been published in leading international journals such as Cell, Nature, and Science. In recent years, innovative drugs targeting the JAK-STAT signaling pathway have been widely used to treat various autoimmune diseases. JAK inhibitors have shown promising results in Phase II clinical trials for tumor immunotherapy. A patent on JAK-STAT signaling, with Professor Shuai as one of the inventors, was successfully used in the development of the drug Promacta (Eltrombopag) for treating aplastic anemia. Novartis' Promacta had annual sales exceeding $2 billion in 2021.

Minoru Takasato Ph.D.

Team leader at RIKEN BDR, Kobe Japan

Dr. Minoru Takasato is an expert in the directed differentiation of human pluripotent stem cells into kidneys. His laboratory focuses on reproducing the process of human organogenesis, using human pluripotent stem cells to generate organoids. In Nature, Published multiple papers in high-level journals such as Nature Methods, Nature Communications, Nature Cell Biology, Cell Stem Cell, et.

Dr. Man (Maya) Zhang

joined Insilico Medicine in 2022 as VP, Head of biology and translational medicine, leading discovery biology and translational medical research. Dr. Zhang has more than 15 years’ working experience in pharmaceutical and biotechnology companies. In 2008 to 2016, Dr. Zhang worked as a function and project leader at Novartis Shanghai site, leading multiple oncology, chronical liver diseases discovery projects. She then joined Hepatitis B DAS in Janssen Shanghai Discovery Center, leading multiple anti-hepatitis B discovery projects. In Hengrui Pharmaceutical, she has established a translational medicine team to support early clinical development of multiple assets including IND enabling, biomarker discovery, indication expansion and drug combination etc. Dr. Zhang obtained Bachelor of Science and Master of Science from the School of Life Sciences of Peking University, China and PhD from the University of Texas at Austin, USA.

Bernd Wollscheid

Bernd Wollscheid, Ph.D., is founder of DISCO Pharmaceuticals. He is a Professor of Molecular Health and Head of the Institute of Translational Medicine at the Department of Health Sciences and Technology at ETH Zürich, Switzerland. As the chairman of EC of the ETH domain Strategic Focus Area, “Personalized Health and Related Technology (PHRT),” he aims to bridge the gap between scientific discoveries and their practical applications in healthcare. Bernd’s research team pioneers developing and applying next-generation technologies at the intersection of biology, chemistry, medicine, and bioinformatics. This research contributes to understanding how molecular nanoscale organization influences cellular function and opens up new opportunities for theranostics.

Bernd studied Chemistry and holds a Ph.D. in Molecular Immunology from the Max Planck Institute of Immunobiology in Freiburg, Germany. He performed post-doctoral research at the Institute of Systems Biology, Seattle, USA.

Wang Jun, PhD in Science

Institute of Microbiology, Chinese Academy of Sciences, Key Laboratory of Immunology and Pathogenic Microorganisms, Chinese Academy of Sciences.

German Max Planck Society Partner Group - Bioinformatics and Computational Biology Research Leader, Researcher.

Main research areas: Bioinformatics and Computational Biology Analysis; Comparison and mining of microbial big data; The application of new sequencing methods and artificial intelligence methods.

The human microbiome refers to the symbiotic ecological community composed of microorganisms within the human body. In recent years, the human microbiome has received high attention in the fields of life sciences and medical research. The complex microbiome is involved in the physiological functions of various systems in the human body, and abnormal microbiota can lead to various diseases, including infections, metabolic diseases, and autoimmune diseases. The applicant pays attention to the core issue in the field of microbiome research - how to identify and use the key groups and action molecules in the microbiome that affect human health and disease efficiently and accurately. The main research achievements include: 1) In the research of infectious diseases, a rapid and accurate method for pathogen detection targeting RNA has been established; A series of novel antimicrobial peptides derived from microorganisms have been discovered through high-throughput artificial intelligence methods for the treatment of drug-resistant pathogens. 2) In metabolic related research, combining the long read long sequence information generated by third-generation sequencing, fine analysis of microbial metabolic potential can be achieved at the strain level; Through the study of gut microbiota rhythms in humans and model animals, key amino acids that affect host gut rhythms and metabolism have been identified and validated. 3) In the study of autoimmune diseases, through clinical collaboration, key "pathogenic" protein components that play a role in the microbiome in immune disorders have been discovered, as well as microbial derived "therapeutic" protein components that can effectively inhibit autoimmune responses.